One might speculate that the upregulation of these inhibitory receptors is tumor-induced, since it is known that iKIRs are strongly associated with NK licensing and ability to limit the immune response and CD94/NKG2A receptor delivers inhibitory signals in both NK cells and CD8+ T cells via interaction with its cognate ligand, HLA-E (76, 77). The gene discussed is KLRD1; the disease is neoplasm.